sulfamethoxazole. Isolates from all of the 60 S. enterica serovar Newport cases included in the present report were susceptible to amikacin, imipenem, and enrofloxacin.
Plasmids were transferred by conjugation from S. enterica serovar Newport strain SRC0307-213 to a nalidixic acid-resistant Escherichia coli recipient strain (ATCC 27662) using nalidixic acid (50 g/ml) and ampicillin (50 g/ml) as the selective agents. Isoelectric focusing (IEF) for ␤-lactamases was performed on all strains at the Centers for Disease Control and Prevention (CDC) using a small-scale freeze-thaw method (12) . Detection of bla CMY and bla TEM genes was performed by PCR at NBC as described previously (18) . Detection of bla SHV was performed at CDC using a modification of the method described by Rasheed and colleagues (19) . Briefly, the bla SHV gene was amplified on a PTC-200 DNA engine (MJResearch, Waltham, MA) in a final volume of 25 l. A final primer concentration of 0.2 M was used, and cycling conditions were as follows: 96°C for 5 min, 35 cycles of 96°C for 1 min, 50°C for 1 min, and 72°C for 1 min, and a final extension at 72°C for 10 min.
␤-Lactamase genes were sequenced using standard methods. Briefly, total genomic DNA was extracted from SRC0307-213 and E. coli transconjugants using a Wizard genomic DNA purification kit (Promega Corp., Madison, WI). ␤-Lactamase genes were amplified with Promega 2ϫ PCR master mix using primers shown in Table 1 . PCR amplicons were cleaned up using a QiaQuick PCR purification kit (QIAGEN, Valencia, CA). Clean amplicons were used to obtain 2ϫ DNA sequence coverage in both directions using a CEQ2000 capillary sequencer (Beckman Coulter, Fullerton, CA), and sequence alignments were performed using SeqManII version 5.06 (DNAStar Inc., Madison, WI).
Salmonella enterica serovar Newport SRC0307-213 was phenotypically negative for ESBL production by double-disk diffusion testing with ceftazidime and ceftazidime-clavulanate and also cefotaxime and cefotaxime-clavulanate (BD BBL Sensi-Disk; Becton Dickinson, Franklin Lakes, NJ) but was positive for bla CMY , bla TEM , and bla SHV genes by PCR. It has been noted previously that the presence of an ESBL can be masked by the expression of an AmpC-like enzyme, such as bla CMY (1, 2, 11) . IEF showed enzymes with pIs of Ն8.4, 8.0, and 5.4, consistent with the CMY, SHV, and TEM enzymes, respectively. Two E. coli transconju-gants (SRC0307-213-1 and SRC0307-213-2) were tested by double-disk diffusion as described above, and both exhibited an ESBL phenotype. Both transconjugant strains were bla TEM and bla SHV positive and negative for the bla CMY gene by PCR. IEF of the transconjugants showed that only two ␤-lactamase genes, encoding enzymes with pIs of 5.4 and 8.0, had transferred, and this was consistent with the fact that the plasmid-mediated ampC gene in serovar Newport strains has previously been shown to be difficult to transfer by conjugation (6) . DNA sequencing of S. enterica serovar Newport strain SRC0307-213 showed that it contained a bla CMY-2 gene. E. coli transconjugant EC0307-213-2 was positive for bla TEM-1b and the extended-spectrum ␤-lactamase gene bla .
ESBL-producing salmonellae are rare in the United States, and this is the first report of an ESBL-producing S. enterica serovar Newport MDR-AmpC strain from animals. bla TEM-1b has frequently been found in Enterobacteriaceae, including Salmonella (10), and the bla SHV-12 gene, first described for E. coli and Klebsiella pneumoniae from Switzerland in 1997, is now becoming increasingly common in Salmonella serotypes from Europe and the United Kingdom but has not yet been described for S. enterica serovar Newport (9, 13, 17, 20, 21) . Isoelectric focusing of ␤-lactamases characterized so far from human S. enterica serovar Newport MDR-AmpC strains submitted to the National Antimicrobial Resistance Monitoring System indicate that many express a putative TEM enzyme, but none show enzymes in the range expected for SHV ␤-lactamases (data not shown). The identification of ESBL genes in S. enterica serovar Newport MDRAmpC has considerable implications for veterinary and public health. Carriage of multiple ␤-lactamase genes is disconcerting because certain combinations of genes could effectively limit all ␤-lactam therapeutic options.
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